Jun 12, 2018 7:30am EDT ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer's Disease
Apr 10, 2018 7:30am EDT ProMIS Neurosciences Announces Publication of Peer Reviewed Scientific Paper Describing a Novel Target on Toxic Oligomers of Amyloid Beta in Alzheimer's Disease
Apr 03, 2018 7:30am EDT ProMIS Neurosciences Announces Appointment of Ernest Bush as Head of Pharmacology/Toxicology and Russell Blacher as Head of Manufacturing
Mar 07, 2018 7:30am EST ProMIS Neurosciences Announces Gross Proceeds of $1,484,498 Related to the Exercise of Common Stock Warrants
Mar 06, 2018 7:30am EST ProMIS Neurosciences Lead Product Candidate for Alzheimer's Disease Shows Potential for Improved Therapeutic Potency versus Other Amyloid Beta-Directed Antibodies